ArticleInternational journal of cancer2026
Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To evaluate the efficacy and safety of the RMT regimen as first-line induction therapy for primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), we retrospectively analyzed 36 patients treated with 4-6 cycles of RMT. After 4 induction cycles, the overall response rate and complete response rate were 97.2% and 80.6%, respectively. With a median follow-up of 19.9 months, the 2-year progression-free survival (PFS) and overall survival rates were 64.4% and 79.3%. The 2-year PFS was 100% in patients receiving sequential autologous stem cell transplantation (ASCT), 67.9% with maintenance therapy (BTKi/IMiD), and 45.5% with induction only. The most common Grades 3-4 adverse event was neutropenia (33.3%); all were manageable without treatment discontinuation. These findings indicate that the RMT regimen demonstrates excellent efficacy and a favorable safety profile in PCNS-DLBCL, including elderly patients; sequential ASCT is the preferred consolidation strategy, while BTKi/IMiD maintenance provides a viable alternative for sustained disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.